Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dimitrios Ntountaniotis is active.

Publication


Featured researches published by Dimitrios Ntountaniotis.


Molecular Pharmaceutics | 2015

Investigation of the interactions of silibinin with 2-hydroxypropyl-β-cyclodextrin through biophysical techniques and computational methods.

Tahsin F. Kellici; Dimitrios Ntountaniotis; Georgios Leonis; Maria V. Chatziathanasiadou; Alexandra V. Chatzikonstantinou; Johanna Becker-Baldus; Clemens Glaubitz; Andreas G. Tzakos; Kyriakos Viras; Petros Chatzigeorgiou; Stavros Tzimas; Evangelia Kefala; Georgia Valsami; Helen Archontaki; Manthos G. Papadopoulos; Thomas Mavromoustakos

Cyclodextrins (CDs) are a well-known class of supermolecules that have been widely used to protect drugs against conjugation and metabolic inactivation as well as to enhance the aqueous solubility and hence to ameliorate the oral bioavailability of sparingly soluble drug molecules. The hepatoprotectant drug silibinin can be incorporated into CDs, and here we elucidate the interaction between the drug and the host at the molecular level. The complexation product of silibinin with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) is characterized by Differential Scanning Calorimetry, mass spectrometry, solid and liquid high-resolution NMR spectroscopy. The chemical shift changes using (13)C CP/MAS on the complexing of the guest with the host provided significant information on the molecular interactions, and they were in agreement with the 2D NOESY results. These results point out that in both solid and liquid forms, the drug is engulfed and interacts with HP-β-CD in identical manner. Molecular dynamics calculations have been performed to examine the thermodynamic characteristics associated with the silibinin-HP-β-CD interactions and to study the stability of the complex. To approximate the physiological conditions, the aqueous solubility and dissolution characteristics of the complex at pH states simulating those of the upper gastrointestinal tract have been applied. To evaluate the antiproliferative activity of silibinin-HP-β-CD complex comparatively to silibinin in MCF-7 human cancer cells, MTT assays have been performed.


Biochimica et Biophysica Acta | 2011

Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers

Dimitrios Ntountaniotis; Gregor Mali; Simona Golic Grdadolnik; Halabalaki Maria; Alexios-Leandros Skaltsounis; Constantinos Potamitis; Eleni Siapi; Petros Chatzigeorgiou; Michael Rappolt; Thomas Mavromoustakos

It is proposed that AT1 antagonists (ARBs) exert their biological action by inserting into the lipid membrane and then diffuse to the active site of AT1 receptor. Thus, lipid bilayers are expected to be actively involved and play a critical role in drug action. For this reason, the thermal, dynamic and structural effects of olmesartan alone and together with cholesterol were studied using differential scanning calorimetry (DSC), 13C magic-angle spinning (MAS) nuclear magnetic resonance (NMR), cross-polarization (CP) MAS NMR, and Raman spectroscopy as well as small- and wide angle X-ray scattering (SAXS and WAXS) on dipalmitoyl-phosphatidylcholine (DPPC) multilamellar vesicles. 13C CP/MAS spectra provided direct evidence for the incorporation of olmesartan and cholesterol in lipid bilayers. Raman and X-ray data revealed how both molecules modify the bilayers properties. Olmesartan locates itself at the head-group region and upper segment of the lipid bilayers as 13C CP/MAS spectra show that its presence causes significant chemical shift changes mainly in the A ring of the steroidal part of cholesterol. The influence of olmesartan on DPPC/cholesterol bilayers is less pronounced. Although, olmesartan and cholesterol are residing at the same region of the lipid bilayers, due to their different sizes, display distinct impacts on the bilayers properties. Cholesterol broadens significantly the main transition, abolishes the pre-transition, and decreases the membrane fluidity above the main transition. Olmesartan is the only so far studied ARB that increases the gauche:trans ratio in the liquid crystalline phase. These significant differences of olmesartan may in part explain its distinct pharmacological profile.


Molecular Informatics | 2011

Conformational Properties and Energetic Analysis of Aliskiren in Solution and Receptor Site

Aggeliki Politi; Georgios Leonis; Haralambos Tzoupis; Dimitrios Ntountaniotis; Manthos G. Papadopoulos; Simona Golic Grdadolnik; Thomas Mavromoustakos

Aliskiren is the first orally active, direct renin inhibitor to be approved for the treatment of hypertension. Its structure elucidation and conformational analysis were explored using 1D and 2D NMR spectroscopy, as well as random search and molecular dynamics (MD) simulations. For the first time, MD calculations have also been performed for aliskiren at the receptor site, in order to reveal its molecular basis of action. It is suggested that aliskiren binds in an extended conformation and is involved in several stabilizing hydrogen bonding interactions with binding cavity (Asp32/255, Gly34) and other binding‐cavity (Arg74, Ser76, Tyr14) residues. Of paramount importance is the finding of a loop consisting of residues around Ser76 that determines the entrapping of aliskiren into the active site of renin. The details of this mechanism will be the subject of a subsequent study. Additionally molecular mechanics Poisson–Boltzmann surface area (MM–PBSA) free energy calculations for the aliskiren‐renin complex provided insight into the binding mode of aliskiren by identifying van der Waals and nonpolar contribution to solvation as the main components of favorable binding interactions.


Current Medicinal Chemistry | 2015

Leveraging NMR and X-ray Data of the Free Ligands to Build Better Drugs Targeting Angiotensin II Type 1 G-Protein Coupled Receptor.

Tahsin F. Kellici; Dimitrios Ntountaniotis; Eftichia Kritsi; Maria Zervou; Panagiotis Zoumpoulakis; Constantinos Potamitis; Serdar Durdagi; Ramin Ekhteiari Salmas; Gizem Ergun; Ebru Gokdemir; Maria Halabalaki; Ioannis P. Gerothanassis; George Liapakis; Andreas G. Tzakos; Thomas Mavromoustakos

The angiotensin II type 1 receptor (AT1R) has been recently crystallized. A new era has emerged for the structure-based rational drug design and the synthesis of novel AT1R antagonists. In this critical review, the X-ray crystallographic data of commercially available AT1R antagonists in free form are analyzed and compared with the conformational analysis results obtained using a combination of NMR spectroscopy and Molecular Modeling. The same AT1R antagonists are docked and compared in terms of their interactions in their binding site using homology models and the crystallized AT1R receptor. Various aspects derived from these comparisons regarding rational drug design are outlined.


Biochimica et Biophysica Acta | 2012

Comparative study of the AT1 receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers

Charalambos Fotakis; Grigorios Megariotis; Dionysios Christodouleas; Eftichia Kritsi; Panagiotis Zoumpoulakis; Dimitrios Ntountaniotis; Maria Zervou; Constantinos Potamitis; Aden Hodzic; Georg Pabst; Michael Rappolt; Gregor Mali; Johanna Baldus; Clemens Glaubitz; Manthos G. Papadopoulos; Antreas Afantitis; Georgia Melagraki; Thomas Mavromoustakos

Drug-membrane interactions of the candesartan cilexetil (TCV-116) have been studied on molecular basis by applying various complementary biophysical techniques namely differential scanning calorimetry (DSC), Raman spectroscopy, small and wide angle X-ray scattering (SAXS and WAXS), solution ¹H and ¹³C nuclear magnetic resonance (NMR) and solid state ¹³C and ³¹P (NMR) spectroscopies. In addition, ³¹P cross polarization (CP) NMR broadline fitting methodology in combination with ab initio computations has been applied. Finally molecular dynamics (MD) was applied to find the low energy conformation and position of candesartan cilexetil in the bilayers. Thus, the experimental results complemented with in silico MD results provided information on the localization, orientation, and dynamic properties of TCV-116 in the lipidic environment. The effects of this prodrug have been compared with other AT₁ receptor antagonists hitherto studied. The prodrug TCV-116 as other sartans has been found to be accommodated in the polar/apolar interface of the bilayer. In particular, it anchors in the mesophase region of the lipid bilayers with the tetrazole group oriented toward the polar headgroup spanning from water interface toward the mesophase and upper segment of the hydrophobic region. In spite of their localization identity, their thermal and dynamic effects are distinct pointing out that each sartan has its own fingerprint of action in the membrane bilayer, which is determined by the parameters derived from the above mentioned biophysical techniques.


Biochimica et Biophysica Acta | 2014

The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan.

Dimitrios Ntountaniotis; Tahsin F. Kellici; Andreas G. Tzakos; Pinelopi Kolokotroni; Theodore Tselios; Johanna Becker-Baldus; Clemens Glaubitz; Sonyan Lin; Alexandros Makriyannis; Thomas Mavromoustakos

ΑΤ1 receptor (AT1R) antagonists exert their antihypertensive effects by preventing the vasoconstrictive hormone AngII to bind to the AT1 receptor. It has been proposed that these biological effects are mediated through a two-step mechanism reaction. In the first step, they are incorporated in the core of the lipid bilayers and in the second step they reach the active site of the receptor through lateral diffusion. In this model, drug/membrane interactions are key elements for the drugs achieving inhibition at the AT1 receptor. In this work, the interactions of the prodrug candesartan cilexetil (TCV-116) with lipid bilayers are studied at molecular detail. Solid-state (13)C-CP/MAS, 2D (1)H-(1)H NOESY NMR spectroscopy and in silico calculations are used. TCV-116 and olmesartan, another drug which acts as an AT1R antagonist are compared for their dynamic effects in lipid bilayers using solid-state (2)H-NMR. We find a similar localization of TCV-116 compared to other AT1 antagonists in the intermediate polar region. In addition, we can identify specific local interactions. These interactions may be associated in part with the discrete pharmacological profiles observed for different antagonists.


Biochimica et Biophysica Acta | 2015

Comparative study of interactions of aliskiren and AT1 receptor antagonists with lipid bilayers.

A. Sadeghpour; Michael Rappolt; Dimitrios Ntountaniotis; Petros Chatzigeorgiou; Kyriakos Viras; Grigorios Megariotis; Manthos G. Papadopoulos; E. Siapi; Gregor Mali; Thomas Mavromoustakos

The renin-angiotensin-aldosterone system (RAAS) plays a key role in the regulation of blood pressure. Renin is the rate limiting enzyme of the RAAS and aliskiren is a highly potent and selective inhibitor of the human renin. Renin is known to be active both in the circulating blood stream as well as locally, when bound to the (pro)-renin receptor ((P)RR). In this study we have investigated a possible mechanism of action of aliskiren, in which its accumulation in the plasma membrane is considered as an essential step for effective inhibition. Aliskirens interactions with model membranes (cholesterol rich and poor) have been investigated by applying different complementary techniques: differential scanning calorimetry (DSC), Raman spectroscopy, magic angle spinning (MAS) nuclear magnetic resonance (NMR) spectroscopy and small- and wide-angle X-ray scattering (SAXS and WAXS). In addition, in silico molecular dynamics (MD) calculations were applied for further confirmation of the experimental data. Aliskirens thermal effects on the pre- and main transition of dipalmitoyl-phosphatidylcholine (DPPC) membranes as well as its topographical position in the bilayer show striking similarities to those of angiotensin II type 1 receptor (AT1R) antagonists. Moreover, at higher cholesterol concentrations aliskiren gets expelled from the membrane just as it has been recently demonstrated for the angiotensin receptor blocker (ARB) losartan. Thus, we propose that both the AT1R and the (P)RR-bound renin active sites can be efficiently blocked by membrane-bound ARBs and aliskiren when cholesterol rich membrane rafts/caveolae are formed in the vicinity of the receptors.


Combinatorial Chemistry & High Throughput Screening | 2014

An Efficient Synthetic Method and Theoretical Calculations of Olmesartan Methyl Ether: Study of Biological Function of AT1 Antagonism

Dimitrios Ntountaniotis; George Agelis; Amalia Resvani; Maria Halabalaki; George Liapakis; Katerina Spyridaki; Simona Golic Grdadolnik; Franci Merzel; Sarantos Kostidis; Constantinos Potamitis; Theodore Tselios; John Matsoukas; Leandros Skaltsounis; Thomas Mavromoustakos

The dissolution of the antihypertensive AT1 antagonist olmesartan in methanol generates in situ a new highly bioactive methyl ether analogue via SN1 mechanism involving an intramolecular proton transfer from carboxyl to hydroxyl group. Theoretical calculations confirmed the thermodynamic control preference of methyl ether versus the antagonistic product methyl ester. Α facile synthetic method for olmesartan methyl ether from olmesartan or olmesartan medoxomil is also described. Interestingly, the introduction of the methyl group to olmesartan did not alter its pharmacological properties. This observation opens new avenues in the synthesis of novel drugs, since hydroxyl and carboxylate groups have an orthogonal relationship in many drugs.


Biochimica et Biophysica Acta | 2013

Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices

George Agelis; Amalia Resvani; Dimitrios Ntountaniotis; Petros Chatzigeorgiou; Catherine Koukoulitsa; M.E. Androutsou; P. Plotas; John Matsoukas; Thomas Mavromoustakos; Tomaž Čendak; T. Ukmar Godec; Gregor Mali

The present work describes the drug:membrane interactions and a drug delivery system of the novel potent AT1 blocker BV6. This designed analog has most of the pharmacological segments of losartan and an additional biphenyltetrazole moiety resulting in increased lipophilicity. We found that BV6:membrane interactions lead to compact bilayers that may in part explain its higher in vitro activity compared to losartan since such environment may facilitate its approach to AT1 receptor. Its high docking score to AT1 receptor stems from more hydrophobic interactions compared to losartan. X-ray powder diffraction (XRPD) and thermogravimetric analysis (TGA) have shown that BV6 has a crystalline form that is not decomposed completely up to 600°C. These properties are desirable for a drug molecule. BV6 can also be incorporated into a mesoporous silicate drug-delivery matrix SBA-15. The properties of the obtained drug-delivery system have been inspected by XRD, (13)C CP/MAS, TGA and nitrogen sorption experiments.


Journal of Biomolecular Structure & Dynamics | 2017

A combined NMR and molecular dynamics simulation study to determine the conformational properties of rat/mouse 35-55 myelin oligodendrocyte glycoprotein epitope implicated in the induction of experimental autoimmune encephalomyelitis

Dimitrios Ntountaniotis; Μarianna Vanioti; Golfo G. Kordopati; Tahsin F. Kellici; Konstantinos D. Marousis; Thomas Mavromoustakos; Georgios A. Spyroulias; Simona Golic Grdadolnik; Theodore Tselios

A combined NMR and molecular dynamics simulation study to determine the conformational properties of rat/mouse 35-55 myelin oligodendrocyte glycoprotein epitope implicated in the induction of experimental autoimmune encephalomyelitis Dimitrios Ntountaniotis, Μarianna Vanioti, Golfo G. Kordopati, Tahsin F. Kellici , Konstantinos D. Marousis, Thomas Mavromoustakos* , Georgios A. Spyroulias, Simona Golic Grdadolnik and Theodore V. Tselios* Department of Chemistry, National and Kapodistrian University of Athens, Zografou 15771, Athens, Greece; Department of Chemistry, University of Patras, Patras 26504, Greece; Department of Chemistry, University of Ioannina, Ioannina 45110, Greece; Department of Pharmacy, University of Patras, Patras 26504, Greece; Department of Biomolecular Structure, National Institute of Chemistry, Hajdrihova 19, SI-1001 Ljubljana, Slovenia

Collaboration


Dive into the Dimitrios Ntountaniotis's collaboration.

Top Co-Authors

Avatar

Thomas Mavromoustakos

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

Tahsin F. Kellici

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Constantinos Potamitis

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Petros Chatzigeorgiou

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

Clemens Glaubitz

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Grigorios Megariotis

National Technical University of Athens

View shared research outputs
Researchain Logo
Decentralizing Knowledge